Table II.

The clinical and radiological characteristics of patients in the training and validation cohorts.

A, Clinical characteristics
	Training cohort (n=99)			Validation cohort (n=43)
Characteristic	MP (n=37)	MN (n=62)	P-valuea	MP (n=16)	MN (n=27)	P-valuea	P-valueb
Sex			0.931c			0.723c	0.805c
Male	32	54		15	23
Female	5	8		1	4
Mean age ± SD, years	57.49±9.56	56.45±9.71	0.607e	55.88±8.63	55.41±8.00	0.858e	0.456e
AFP, ng/ml			0.025c			0.038c	0.715c
≤7	9	32		5	16
7–400	17	20		5	9
>400	11	10		6	2
Location			0.561c			0.372c	0.581c
Right	31	49		10	23
Left	6	13		6	4
HBsAg			0.325c			0.614c	0.668c
Positive	26	49		12	22
Negative	11	13		4	5
HCV-Ab			1.000c			1.000d	0.989c
Positive	1	3		0	1
Negative	36	59		16	26
Differentiation			0.026c			0.034d	0.565c
Well	2	3		0	4
Moderate	19	47		9	20
Poor	16	12		7	3
B, Radiological characteristics
	Training cohort (n=99)			Validation cohort (n=43)
Characteristic	MP (n=37)	MN (n=62)	P-valuea	MP (n=16)	MN (n=27)	P-valuea	P-valueb
MTD, cm	3.82±0.88	3.21±0.94	0.002e	3.75±0.80	2.92±0.62	<0.001e	0.231e
Background liver			0.690c			0.358c	0.553c
Noncirrhosis	14	21		3	10
Cirrhosis	23	41		13	17
Tumor encapsulation			0.805c			0.362c	0.534c
Absent	11	17		2	8
Present	26	45		14	19
Fast wash-in			0.292c			0.929c	0.742c
Yes	30	55		14	22
No	7	7		2	5
Fast wash-out			0.409c			0.534c	0.720c
Yes	24	35		11	16
No	13	27		5	11
Tumor necrosis			0.638c			0.372c	0.668c
Absent	29	46		11	23
Present	8	16		5	4

MP, microvascular invasion-positive; MN, microvascular invasion-negative; AFP, α-fetoprotein; HBsAg, hepatitis B surface antigen; MTD, maximum tumor diameter; HCV-Ab, hepatitis C antibody.

^aMP vs. MN

^bTraining cohort vs. validation cohort

^cP-values calculated using the χ² test

^dP-values calculated using Fisher's exact test

^eP-values calculated using the independent t-test.